3-hydroxyflavanone profile

3-hydroxyflavanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'-hydroxyflavanone : A monohydroxyflavanone in which the hydroxy group is located at position 3'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3534982
CHEMBL ID	485021
CHEBI ID	48022
SCHEMBL ID	5088596
MeSH ID	M0443191

Synonym
TIMTEC1_006574
3'-hydroxyflavanone
3'-hydroxy flavanone
2-(3-hydroxyphenyl)-2,3-dihydro-4h-chromen-4-one
2-(3-hydroxyphenyl)chroman-4-one
CHEBI:48022 ,
MLS001360502
smr001223897
HMS1552K18
CHEMBL485021
2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one
H1025
92496-65-6
ST058458
HMS3040B14
3-hydroxyflavanone
AKOS015856154
SCHEMBL5088596
JVSPTYZZNUXJHN-UHFFFAOYSA-N
4h-1-benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)-
unii-5o4my88w2v
5O4MY88W2V ,
3'-hydroxyflavanone, (+/-)-
2,3-dihydro-2-(3-hydroxyphenyl)-4h-1-benzopyran-4-one
mfcd00017738
3''-hydroxyflavanone
3''''-hydroxyflavanone
bdbm50488649
DTXSID1022344
Q27120908
D90992
DTXSID50393419
CS-0330266

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monohydroxyflavanone	Any hydroxyflavanone carrying a single hydroxy substituent.
3'-hydroxyflavanones	Any hydroxyflavanone with a hydroxy substituent at position 3' of the phenyl ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	37.9330	0.0072	15.7588	89.3584	AID588342
Nrf2	Homo sapiens (human)	Potency	15.8489	0.0920	8.2222	23.1093	AID624171
ATAD5 protein, partial	Homo sapiens (human)	Potency	19.9526	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	27.5110	0.0008	11.3822	44.6684	AID686978; AID686979
P53	Homo sapiens (human)	Potency	11.2202	0.0731	9.6858	31.6228	AID504706
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	89.1251	3.5481	19.5427	44.6684	AID743266
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	35.4813	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID423365	Binding affinity to Enterococcus faecalis KAS3 by fluorescence quenching analysis	2009	Journal of natural products, Apr, Volume: 72, Issue:4	Screening of flavonoids as candidate antibiotics against Enterococcus faecalis.
AID423362	Antimicrobial activity against Enterococcus faecalis after 20 hrs by broth microdilution method	2009	Journal of natural products, Apr, Volume: 72, Issue:4	Screening of flavonoids as candidate antibiotics against Enterococcus faecalis.
AID353304	Increase in EGR1 mRNA expression in human HeLa cells after 1 hr by Western blotting	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression.
AID423363	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis after 20 hrs by broth microdilution method	2009	Journal of natural products, Apr, Volume: 72, Issue:4	Screening of flavonoids as candidate antibiotics against Enterococcus faecalis.
AID353303	Increase in EGR1 mRNA expression in human HEK293 cells at 20 ug/mL after 6 to 12 hrs by dual-glo luciferase assay relative to control	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (6.25)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (31.25)	29.6817
2010's	8 (50.00)	24.3611
2020's	2 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbon monoxide Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.	2.31	1	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
taxifolin [no description available]	2.05	1	3'-hydroxyflavanones; 4'-hydroxyflavanones; dihydroflavonols; pentahydroxyflavanone; secondary alpha-hydroxy ketone
7-hydroxyflavanone 7-hydroxyflavanone: structure given in first source. 7-hydroxyflavanone : A monohydroxyflavanone that is flavanone substituted by a hydroxy group at position 7.	2.45	2	monohydroxyflavanone
flavanone flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.	2.45	2	flavanones
pinocembrin pinocembrin : A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea.	2.45	2	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent
hesperetin [no description available]	2.05	1	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite
pinostrobin [no description available]	2.05	1	monohydroxyflavanone; monomethoxyflavanone	antidote; plant metabolite
sakuranetin sakuranetin: major rice phytoalexin; RN given for ((S)-(-))-isomer; structure in first source. sakuranetin : A flavonoid phytoalexin that is (S)-naringenin in which the hydroxy group at position 7 is replaced by a methoxy group.	2.04	1	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; flavonoid phytoalexin; monomethoxyflavanone	antimycobacterial drug; plant metabolite
homoeriodictyol homoeriodictyol: structure in first source. homoeriodictyol : A trihydroxyflavanone that consists of 3'-methoxyflavanone in which the three hydroxy substituents are located at positions 4', 5, and 7.	2.05	1	3'-methoxyflavanones; 4'-hydroxyflavanones; monomethoxyflavanone; trihydroxyflavanone	flavouring agent; metabolite
6-methoxyflavanone 6-methoxyflavanone: structure in first source	2.05	1
4'-methoxyflavanone 4'-methoxyflavanone : The parent member of the class of 4'-methoxyflavanones that is flavanone which is substituted by a methoxy group at the 4'-position.	2.05	1	4'-methoxyflavanones
liquiritigenin liquiritigenin: structure given in first source; isolated from Pterocarpus marsupium. 4',7-dihydroxyflavanone : A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.. liquiritigenin : A dihydroxyflavanone compound having the two hydroxy substituents at the 4'- and 7-positions. Isolated from the root of Glycyrrhizae uralensis, it is a selective agonist for oestrogen receptor beta.	2.01	1	4',7-dihydroxyflavanone	hormone agonist; plant metabolite
4'-hydroxyflavanone 4'-hydroxyflavanone: structure in first source. 4'-hydroxyflavanones : Any hydroxyflavanone having a hydroxy substituent located at position 4'.	2.45	2	4'-hydroxyflavanones; monohydroxyflavanone
2'-hydroxyflavanone [no description available]	2.45	2
sakuranetin [no description available]	2.05	1
5,7-dimethoxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one [no description available]	2.05	1	ether; flavonoids
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	2.45	2	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
taxifolin (+)-taxifolin : A taxifolin that has (2R,3R)-configuration.	2.05	1	taxifolin	metabolite
eriodictyol eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.	2.45	2	3'-hydroxyflavanones; tetrahydroxyflavanone
glycosides [no description available]	1.93	1
sesquiterpenes [no description available]	2.04	1
6-hydroxyflavanone 6-hydroxyflavanone : A monohydroxyflavanone that is flavanone substituted by a hydroxy group at position 6.	2.45	2	monohydroxyflavanone	fungal xenobiotic metabolite
6,3',4'-Trimethoxyflavanone [no description available]	2.05	1	ether; flavonoids
alpinetin alpinetin: from Alpinia henryi K. Schum.; structure in first source	2.05	1	ether; flavonoids
isosilybin a isosilybin A: has antineoplastic activity; structure in first source	2.07	1
2,7,4'-trihydroxyisoflavanone 2,7,4'-trihydroxyisoflavanone: structure in first source. 2,4',7-trihydroxyisoflavanone : A hydroxyisoflavanone that is isoflavanone with hydroxy substituents at positions 2, 7 and 4'.	2.01	1	hydroxyisoflavanone; lactol
dihydrorobinetin dihydrorobinetin: structure in first source	2.05	1
silybin Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.	2.07	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Dermatoses [description not available]	2.31	1
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.31	1

3-hydroxyflavanone

Description

Cross-References

Synonyms (33)

Roles (1)

Drug Classes (2)

Protein Targets (7)

Potency Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (20)

Research

Studies (16)

Market Indicators

Research Demand Index: 11.41

Study Types

3-hydroxyflavanone

Description

Cross-References

Synonyms (33)

Roles (1)

Drug Classes (2)

Protein Targets (7)

Potency Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (20)

Research

Studies (16)

Market Indicators

Research Demand Index: 11.41

Study Types

Related Drugs (28)

Related Conditions (6)